| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Veterans Affairs–Nebraska Western Iowa Health Care System, Omaha, Nebraska 68105; and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska 68178
Address all correspondence and requests for reprints to: Roger D. Reidelberger, Ph.D., Department of Veterans Affairs–Nebraska Western Iowa Health Care System (151), 4101 Woolworth Avenue, Omaha, Nebraska 68105. E-mail: roger.reidelberger{at}med.va.gov.
Peptide YY (3–36) [PYY (3–36)] is postulated to act as a hormonal signal from the gut to the brain to inhibit food intake and gastric emptying. A mixed-nutrient meal produces a prolonged 2–3 h increase in plasma levels of both PYY (3–36) and PYY (1–36). We determined the dose-dependent effects of 3-h iv infusions of PYY (3–36) and PYY (1–36) (0.5–50 pmol·kg–1·min–1) at dark onset on food intake in non-food-deprived rats. PYY (3–36) dose-dependently inhibited food intake: the minimal effective dose was 5 pmol·kg–1·min–1; the estimated potency (mean effective dose) and efficacy (maximal percent inhibition) were 15 pmol·kg–1·min–1 (2.6 nmol/kg) and 47%, respectively. PYY (1–36) was an order of magnitude less potent than PYY (3–36). Similar total doses of PYY (3–36) (0.9–30 nmol/kg) infused during the 15-min period just before dark onset also dose-dependently inhibited food intake, albeit with a lower potency and efficacy. Other experiments showed that PYY (3–36) inhibited food intake in sham-feeding rats and was more effective in reducing intake of a mixed-nutrient liquid diet than 15% aqueous sucrose. We conclude that: 1) iv infusions of PYY (3–36), which are more likely than ip injections to mimic postprandial increases in plasma PYY (3–36), potently inhibit food intake in a dose-dependent manner; 2) PYY (1–36) is an order of magnitude less potent than PYY (3–36); and 3) PYY (3–36) can inhibit food intake independently of its action to inhibit gastric emptying. It remains to be determined whether iv doses of PYY (3–36) that reproduce postprandial increases in plasma PYY (3–36) are sufficient to inhibit food intake.
This article has been cited by other articles:
 |
|
 |
|
  S. Unniappan and T. J. Kieffer Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R51 - R58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Vincent and C W le Roux The satiety hormone peptide YY as a regulator of appetite J. Clin. Pathol., May 1, 2008; 61(5): 548 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. C. Parkinson, W. S. Dhillo, C. J. Small, O. B. Chaudhri, G. A. Bewick, I. Pritchard, S. Moore, M. A. Ghatei, and S. R. Bloom PYY3-36 injection in mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones Am J Physiol Endocrinol Metab, April 1, 2008; 294(4): E698 - E708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. B. Chaudhri, K. Wynne, and S. R. Bloom Can Gut Hormones Control Appetite and Prevent Obesity? Diabetes Care, February 1, 2008; 31(Supplement_2): S284 - S289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Ortiz, L. F. Milardo, L. B. DeCarr, T. M. Buckholz, M. R. Mays, T. H. Claus, J. N. Livingston, C. D. Mahle, and K. J. Lumb A Novel Long-Acting Selective Neuropeptide Y2 Receptor Polyethylene Glycol-Conjugated Peptide Agonist Reduces Food Intake and Body Weight and Improves Glucose Metabolism in Rodents J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 692 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1798 - R1808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R39 - R46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sloth, J. J. Holst, A. Flint, N. T. Gregersen, and A. Astrup Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1062 - E1068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Murphy, W. S. Dhillo, and S. R. Bloom Gut Peptides in the Regulation of Food Intake and Energy Homeostasis Endocr. Rev., December 1, 2006; 27(7): 719 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Ghrelin Attenuates the Inhibitory Effects of Glucagon-Like Peptide-1 and Peptide YY(3-36) on Food Intake and Gastric Emptying in Rats Diabetes, November 1, 2006; 55(11): 3038 - 3046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.-J. D. Lin, A. Sainsbury, N. J. Lee, D. Boey, M. Couzens, R. Enriquez, K. Slack, R. Bland, M. J. During, and H. Herzog Combined Deletion of Y1, Y2, and Y4 Receptors Prevents Hypothalamic Neuropeptide Y Overexpression-Induced Hyperinsulinemia despite Persistence of Hyperphagia and Obesity Endocrinology, November 1, 2006; 147(11): 5094 - 5101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ito, H. ThidarMyint, T. Murata, H. Inoue, R. M. Neyra, and H. Kuwayama Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs. J. Endocrinol., October 1, 2006; 191(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bacha and S. A. Arslanian Ghrelin and Peptide YY in Youth: Are There Race-Related Differences? J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3117 - 3122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vrang, A. N. Madsen, M. Tang-Christensen, G. Hansen, and P. J. Larsen PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2006; 291(2): R367 - R375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ahituv, N. Kavaslar, W. Schackwitz, A. Ustaszewska, J. M. Collier, S. Hebert, H. Doelle, R. Dent, L. A. Pennacchio, and R. McPherson A PYY Q62P variant linked to human obesity Hum. Mol. Genet., February 1, 2006; 15(3): 387 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, J. R. Reeve Jr., D. A. Keire, and R. D. Reidelberger Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2006; 290(2): R298 - R305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Young Obesity: A Peptide YY-Deficient, But Not Peptide YY- Resistant, State Endocrinology, January 1, 2006; 147(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
C. W. le Roux, R. L. Batterham, S. J. B. Aylwin, M. Patterson, C. M. Borg, K. J. Wynne, A. Kent, R. P. Vincent, J. Gardiner, M. A. Ghatei, et al. Attenuated Peptide YY Release in Obese Subjects Is Associated with Reduced Satiety Endocrinology, January 1, 2006; 147(1): 3 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Adams, C. Lei, C. M. Jodka, S. E. Nikoulina, J. A. Hoyt, B. Gedulin, C. M. Mack, and E. S. Kendall PYY[3-36] Administration Decreases the Respiratory Quotient and Reduces Adiposity in Diet-Induced Obese Mice J. Nutr., January 1, 2006; 136(1): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Roth, P. J. Enriori, K. Harz, J. Woelfle, M. A. Cowley, and T. Reinehr Peptide YY Is a Regulator of Energy Homeostasis in Obese Children before and after Weight Loss J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6386 - 6391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Siahanidou, H. Mandyla, M. Vounatsou, D. Anagnostakis, I. Papassotiriou, and G. P. Chrousos Circulating Peptide YY Concentrations Are Higher in Preterm than Full-Term Infants and Correlate Negatively with Body Weight and Positively with Serum Ghrelin Concentrations Clin. Chem., November 1, 2005; 51(11): 2131 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Talsania, Y. Anini, S. Siu, D. J. Drucker, and P. L. Brubaker Peripheral Exendin-4 and Peptide YY3-36 Synergistically Reduce Food Intake through Different Mechanisms in Mice Endocrinology, September 1, 2005; 146(9): 3748 - 3756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1695 - R1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schonhoff, L. Baggio, C. Ratineau, S. K. Ray, J. Lindner, M. A. Magnuson, D. J. Drucker, and A. B. Leiter Energy Homeostasis and Gastrointestinal Endocrine Differentiation Do Not Require the Anorectic Hormone Peptide YY Mol. Cell. Biol., May 15, 2005; 25(10): 4189 - 4199. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
